Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets

Hormone Research

Volumn 69, Issue 4, 2008, Pages 212-220

  Mäkitie, Outi ^a   Toiviainen Salo, Sanna ^b   Marttinen, Eino ^b   Kaitila, Ilkka ^b   Sochett, Etienne ^c   Sipilä, Ilkka ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Growth hormone; Hypophosphatemia; IGF I; Metabolic control; Rickets

Indexed keywords

1ALPHA HYDROXYVITAMIN D; CALCITRIOL; HUMAN GROWTH HORMONE; PHOSPHATE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BODY GROWTH; BODY HEIGHT; BONE RADIOGRAPHY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; FEMALE; GROWTH DISORDER; HORMONAL THERAPY; HUMAN; HYPOPHOSPHATEMIC RICKETS; LEG MALFORMATION; MALE; MEDICAL PARAMETERS; METABOLIC REGULATION; PARATHYROID FUNCTION; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; X CHROMOSOME LINKED DISORDER;

ADOLESCENT; BODY HEIGHT; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE DEVELOPMENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GROWTH HORMONE; HOMEOSTASIS; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; MALE; PARATHYROID GLANDS; PHOSPHATES; VITAMIN D;

EID: 42449107834     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113021     Document Type: Article

References (36)

1. Albright F, Butler AM, Bloomberg E: Rickets resistant to vitamin D therapy. Am J Dis Child 1937;54:529-547.
2. Chan JCM, Alon U, Hirshman GM: Renal hypophosphatemic rickets. J Pediatr 1985;106:533-544.
3. HYP Consortium: A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130-136.
4. Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO: Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2001;86:3889-3899.
5. Quarles LD, Drezner MK: Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab 2001;86:494-496.
6. White KE, Larsson TM, Econs MJ: The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 2006;27:221-241.
7. Glorieux FH, Scriver CR, Reade TM, Goldman H, Roseborough A: Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med 1972;287:481-487.
8. Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK: Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest 1985;75:1858-1868.
9. Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M: Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 1991;325:1843-1848.
10. Chesney RW, Mazess RB, Rose P, Hamstra AJ, DeLuca HF, Breed AL: Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphorus in X-linked hypophosphatemic rickets. Pediatrics 1983;71:559-567.
11. Friedman NE, Lobaugh B, Drezner MK: Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 1993;76:839-844.
12. Mäkitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E: Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003;88:3591-3597.
13. Miyamoto J, Koto S, Hasegawa Y: Final height of Japanese patients with X-linked hypophosphatemic rickets: effect of vitamin D and phosphate therapy. Endocr J 2000;47:163-167.
14. Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G: Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 2001;138:236-243.
15. Sochett E, Doria AS, Henriques F, Kooh SW, Daneman A, Mäkitie O: Growth and metabolic control during puberty in girls with Xlinked hypophosphataemic rickets. Horm Res 2004;61:252-256.
16. Mäkitie O, Kooh SW, Sochett E: Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol 2003;58:163-168.
17. Gershberg H, Neumann LL, Mari S: Studies on vitamin D-resistant rickets;effects of human growth hormone. Metabolism 1964;13:636-649.
18. Hammerman MR, Karl IE, Hruska KA: Regulation of canine renal vesicle Pi transport by growth hormone and parathyroid hormone. Biochim Biophys Acta 1980;603:322-335.
19. Bianda T, Glatz Y, Bouillon R, Froesch ER, Schmid C: Effects of short-term insulin-like growth factor-I or GH treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults. J Clin Endocrinol Metab 1998;83:81-87.
20. 3. Endocrinology 1990;127:453-459.
21. Saggesse G, Baroncelli GI, Bertelloni S, Perri G: Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J Pediatr 1995;127:395-402.
22. Lanes R, Harrison HE: Growth hormone therapy in a poorly growing child with hypophosphatemic rickets. J Endocrinol Invest 1990;13:833-837.
23. Wilson DM, Lee PDK, Morris AH, Reiter EO, Gertner JM, Marcus R, Quarmby VE, Rosenfeld RG: Growth hormone therapy in hypophosphatemic rickets. Am J Dis Child 1991;145:1165-1170.
24. Haffner D, Wuhl E, Blum WF, Schaefer F, Mehls O: Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphatemia. Eur J Pediatr 1995;154:610-613.
25. Seikaly MG, Brown R, Baum M: The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics 1997;100:879-884.
26. Sorva R, Lankinen S, Tolppanen EM, Perheentupa J: Variation of growth in height and weight of children. II. After infancy. Acta Paediatr Scand 1990;79:498-506.
27. Marttinen E: The Growth of Hand Bones in Relation to Some Body Dimensions in Normal Children and in Certain Forms of Short Stature (in Finnish);thesis, Helsinki 1983.
28. Tanner JM: Growth at Adolescence. Oxford, Blackwell Scientific, 1962.
29. Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
30. Bachrach LK, Hastie T, Wang MC, Narasimhan B, Marcus R: Bone mineral acquisition in healthy Asian, Hispanic, Black and Caucasian youth. A longitudinal study. J Clin Endocrinol Metab 1999;84:4702-4712.
31. Zoidis E, Zapf J, Schmid C: Phex cDNA cloning from rat bone and studies on phex mRNA expression: tissue specificity, age dependency, and regulation by insulin-like growth factor I in vivo. Mol Cell Endocrinol 2000;168:41-51.
32. Patel L, Clayton PE, Brain C, Pelekouda E, Addison GM, Price DA, Mughal MZ: Acute biochemical effects of growth hormone treatment compared with conventional treatment in familial hypophosphataemic rickets. Clin Endocrinol 1996:44:687-696.
33. Reusz GS, Miltenyi G, Stubnya G, Szabo A, Horvath C, Byrd DJ, Peter F, Tulassay T: X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol 1997;11:573-577.
34. Minuto F, Palermo C, Arvigo M, Barreca AM: The IGF system and bone. J Endocrinol Invest 2005;28:8-10.
35. Cruickshank J, Grossman DI, Peng RK, Famula TR, Oberbauer AM: Spatial distribution of growth hormone receptor, insulin-like growth factor-I receptor and apoptotic chondrocytes during growth plate development. J Endocrinol 2005;184:543-553.
36. Ueland T: GH/IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 2005;152:327-332.